Pricol Limited Annual Disclosure on Promoter Share Encumbrances

Pricol Limited has released its annual declaration regarding promoter share encumbrances for the financial year 2025-2026. The company and its promoter group have confirmed that no new encumbrances have been created on their shares in the company, either directly or indirectly, beyond what may have been previously disclosed. This transparency measure ensures that shareholders and investors remain informed about the status of promoter holdings and potential liabilities linked to their equity stakes.

Commitment to Transparency

In accordance with standard corporate governance practices, Pricol Limited has formally communicated the status of promoter-held shares as of April 2, 2026. The declaration confirms that the promoter group has maintained a clean record regarding share pledging activities throughout the 2025-2026 financial year. By verifying that no unannounced encumbrances exist, the leadership team aims to preserve investor confidence and uphold the company’s integrity.

Promoter Group Participation

The submission includes formal declarations from key members of the promoter group, including Mr. Vijay Mohan, Mrs. Vanitha Mohan, Mr. Vikram Mohan, Mr. Viren Mohan, Ms. Madhura Mohan, and Ms. Manasa Mohan. Additionally, corporate entities within the promoter group, such as Shrimay Enterprises Private Limited, Pricol Holdings Private Limited, Pricol Engineering Industries Private Limited, and Pricol Logistics Private Limited, have all provided individual confirmations regarding their respective shareholdings.

Impact on Stakeholders

This proactive disclosure is intended to provide clarity to the markets and the company’s stakeholders. By confirming that their shareholdings are free from new, undisclosed encumbrances, the promoters reinforce their long-term commitment to the company. This stability in ownership structure remains a key focal point for institutional and retail investors monitoring the company’s governance standards.

Source: BSE

Previous Article

Concord Biotech Limited Strategic Acquisition of Celliimune Biotech

Next Article

Orchid Pharma Credit Ratings Reviewed by CARE Ratings